Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Tanvex BioPharmaTPE:6541 -0.12%48 Receivables Turnover is 2.74 as of Dec. 2025. GuruFocus rates TPE:6541 with a GF Score™ of 48/100. The stock has 4 warning signs investors should review. Among 841 Biotechnology companies, Tanvex BioPharma ranks better than 55.17% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Tanvex BioPharma's Revenue for the
three
months ended in Dec. 2025 was NT$179.0 Mil. Tanvex BioPharma's average Accounts Receivable for the
three
months ended in Dec. 2025 was NT$65.3 Mil.
Hence, Tanvex BioPharma's Receivables Turnover for the
three
months ended in Dec. 2025 was 2.74.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Tanvex BioPharma Receivables Turnover Related Terms
Tanvex BioPharma Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Tanvex BioPharma's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:6541 vs VRTX, REGN, ALNY: Receivables Turnover Comparison
For the Biotechnology subindustry, Tanvex BioPharma's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tanvex BioPharma Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Tanvex BioPharma's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Tanvex BioPharma's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tanvex BioPharma (TPE:6541) has a Receivables Turnover of 2.74 as of Dec. 2025. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Tanvex BioPharma and its competitors. According to the industry distribution chart, Tanvex BioPharma ranks #377 out of 841 companies in the Biotechnology industry, placing it in the top 44.8%.
Is Tanvex BioPharma's Receivables Turnover too high?
Tanvex BioPharma's current Receivables Turnover is 2.74. The Biotechnology industry median Receivables Turnover is 5.28. Tanvex BioPharma's value of 2.74 is 48.1% below this industry median. Based on the distribution chart, Tanvex BioPharma ranks #377 out of 841 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Tanvex BioPharma has a GF Score™ of 48/100, reflecting its overall financial health beyond just this single metric.
How does Tanvex BioPharma's Receivables Turnover compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Tanvex BioPharma ranks #377 out of 841 companies for Receivables Turnover. This puts Tanvex BioPharma in the upper half of its industry. The industry median Receivables Turnover is 5.28. Tanvex BioPharma's value of 2.74 is 48.1% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.28, based on 841 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tanvex BioPharma's current Receivables Turnover of 2.74 is 48.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Tanvex BioPharma and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tanvex BioPharma's current Receivables Turnover is 2.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tanvex BioPharma stock overvalued right now?
Tanvex BioPharma (TPE:6541) has a current Receivables Turnover of 2.74. The current Receivables Turnover is 2.74 and 48.1% below the Biotechnology industry median of 5.28. Tanvex BioPharma's overall GF Score™ is 48/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Tanvex BioPharma (TPE:6541), the current Receivables Turnover is 2.74 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Tanvex BioPharma Inc is a biopharmaceutical company. It is engaged in the research, development, manufacture, and sale of biosimilar products and contract development and manufacturing of biological medicine. The company's products are used to cure diseases such as Neutropenia, Breast Cancer, Metastatic Colorectal Cancer, and others. Geographically, the company operates in Asia, America, Europe, and Australia. The company generates a majority of its revenue from the USA.
48GF Score
Get the complete analysis for TPE:6541
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:6541 has been successfully added to your 
